Here are the DEF 14A proxy statements from Cocrystal Pharma, Inc. (COCP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow COCP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COCP filings page.
Cocrystal Pharma is asking stockholders to vote at its 2026 virtual annual meeting on July 14, 2026. Investors will elect five directors for one-year terms, ratify Weinberg & Company as independent auditor for 2026, and approve a potential adjournment to gather additional votes if needed.
The proxy details how to attend and vote electronically, outlines quorum and broker voting rules, and describes board structure and full independence under Nasdaq standards. It highlights key committees, an insider trading and anti-hedging policy, and a clawback policy tied to financial restatements.
Executive pay in 2025 focused on reduced base salaries and equity awards, with Co-CEOs James Martin and Sam Lee earning $265,000 and $248,672 respectively. The filing shows insiders and directors collectively beneficially owning 39.4% of common stock and reports a 2025 net loss of $8.8 million alongside pay-versus-performance disclosure.